Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Annexin A2 short hairpin RNA (shRNA) is a sequence of RNA designed to silence the expression of the **Annexin A2 (ANXA2)** gene through the RNA interference (RNAi) pathway. Annexin A2 is a calcium-dependent phospholipid-binding protein that plays a critical role in cell surface fibrinolysis, cell-cell adhesion, and signal transduction. In the context of oncology, particularly **bladder cancer (BLCA)**, ANXA2 is often overexpressed and associated with high pathological grades, metastasis, and poor survival. By delivering shRNA—often via lentiviral or plasmid vectors—into target cells, the endogenous RNAi machinery (including the RISC complex) is recruited to degrade ANXA2 mRNA. This downregulation results in decreased cell proliferation, migration, and invasion, as well as a reduction in the secretion of proangiogenic factors and cytokines like IL-6, IL-8, and PDGF-BB.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on annexin A2 short hairpin RNA.